Back to top
more

Fresenius Medical Care AG & Co. (FMS)

(Real Time Quote from BATS)

$21.44 USD

21.44
290,752

-0.49 (-2.23%)

Updated May 21, 2024 03:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 248)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Cerner, AmerisourceBergen, Fresenius and Olympus

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Cerner, AmerisourceBergen, Fresenius and Olympus

    Nabaparna Bhattacharya headshot

    3 Favorable Trends Dispelling Tax-Repeal Worries in MedTech

    by Nabaparna Bhattacharya

    Here we analyze how the U.S. MedTech space is gearing up to counter the disquieting CBO projections regarding federal deficit.

      Nabaparna Bhattacharya headshot

      Fresenius Medical (FMS) Q4 Earnings Beat, View Impressive

      by Nabaparna Bhattacharya

      Higher sales of dialyzers, machines, peritoneal dialysis products, renal pharmaceuticals, bloodlines and products for acute care boost Fresenius Medical (FMS) in Q4.

        Here's Why You Should Sweep Up Quest Diagnostics Right Now

        by Zacks Equity Research

        Quest Diagnostics' (DGX) latest acquisitions boost investors' confidence.

          Becton, Dickinson Gains on Strong Q1 Results & Acquisitions

          by Zacks Equity Research

          Acquisition of C.R.Bard and a solid FY18 guidance are key catalysts for Becton, Dickinson (BDX).

            Quest Diagnostics Buys Fresenius Medical's Shiel Laboratory

            by Zacks Equity Research

            Quest Diagnostics (DGX) focuses on driving growth and operational efficiency through acquisitions.

              Becton, Dickinson Focuses on Medication Management, Stock Up

              by Zacks Equity Research

              Management at Becton, Dickinson and Company (BDX) has been focusing on strengthening its portfolio for long.

                Here's Why You Should Offload Fresenius Medical Stock Now

                by Zacks Equity Research

                Fresenius (FMS) grapples with multiple issues. An unfavorable estimate revision trend adds to the woes.

                  Fresenius Medical (FMS) Q3 Earnings Miss, FY17 View Intact

                  by Zacks Equity Research

                  Strong growth in Health Care Products and Health Care Services segments drove Fresenius's (FMS) third-quarter revenues. Lackluster performance by the renal pharmaceutical segment is a concern.

                    5 MedTech Momentum Picks Investors Will Love

                    by Zacks Equity Research

                    In a volatile political environment, seasoned investors should focus on momentum stocks as winning bets to tide over the uncertainty.

                      Fresenius Medical (FMS) Well Poised on Growth Strategy 2020

                      by Zacks Equity Research

                      Fresenius Medical (FMS) is banking on its Growth Strategy 2020 plan for gaining market traction in the future. However, lackluster performance in the bourse is a concern.

                        Keryx Focuses on Kidney Drug Auryxia Despite Generic Threat

                        by Zacks Equity Research

                        Keryx (KERX) is working on expanding its only marketed product, Auryxia's label.

                          Abiomed's Latest Regulatory Progress Boosts Impella Line

                          by Zacks Equity Research

                          We believe that robust demand for Impella products will continue to drive Abiomed's (ABMD) top line over the long term.

                            Fresenius Medical Opens Manufacturing Plant in Malaysia

                            by Zacks Equity Research

                            Fresenius Medical's (FMS) Malaysian plant will strengthen the company's presence in the rapidly-growing market.

                              C. R. Bard's (BCR) LUTONIX 035 Gets FDA Pre-Market Approval

                              by Zacks Equity Research

                              The early market acceptance of the LUTONIX platform has been impressive and C. R. Bard (BCR) is likely to witness an expanded adoption of this technology as the market continues to mature.

                                Invacare (IVC) Introduces TDX SP2 Power Wheelchair Globally

                                by Zacks Equity Research

                                Invacare Corporation's (IVC) newly launched TDX SP2 Power Wheelchair would greatly help in capturing the highly competitive global wheelchair market.

                                  NxStage Medical Partners Dialyze Direct for On-Site Dialysis

                                  by Zacks Equity Research

                                  The latest development will lend NxStage Medical (NXTM) a competitive edge in the hemodialysis dialysis market. The company will leverage on its System One platform for treating patients with ESRD.

                                    PRA Health Sciences (PRAH) Prices Secondary Stock Offering

                                    by Zacks Equity Research

                                    PRA Health Sciences' (PRAH) move to procure funds through secondary offering is likely to enhance its bottom line and shareholders' returns.

                                      Varian Medical (VAR) Signs Distribution Deal with Bionix

                                      by Zacks Equity Research

                                      Varian Medical's (VAR) new distribution agreement with Bionix Radiation Therapy would strengthen its radiotherapy business in North America.

                                        Meridian (VIVO) Initiates illumigene CMV Trial, Shares Shine

                                        by Zacks Equity Research

                                        Solid share price rally following the news suggests that the latest development is likely to buoy Meridian's (VIVO) bottom line and enhance its illumigene platform.

                                          Fresenius Medical Inks $2B Deal to Take Over NxStage Medical

                                          by Zacks Equity Research

                                          Fresenius Medical's (FMS) latest development is expected to fortify the company's foothold in the Home dialysis market, particularly in the renal care space.

                                            DENTSPLY (XRAY) Earnings and Revenues Miss Estimates in Q2

                                            by Zacks Equity Research

                                            DENTSPLY SIRONA (XRAY) reported lukewarm second-quarter results owing to inventory reduction related to a change in the distribution strategy in North America and lower equipment sales to end users.

                                              Luminex (LMNX) Beats Earnings & Revenue Estimates in Q2

                                              by Zacks Equity Research

                                              Luminex's (LMNX) assay business will be its key driver over the long term. The FDA go-ahead for Luminex ARIES Bordetella and ARIES C. Difficile assay were the key highlights of the second quarter.

                                                Evolent Health (EVH) Posts Q2 Loss as Expected, Revenues Top

                                                by Zacks Equity Research

                                                Evolent Health's (EVH) strong rise in the number of members on its platform was the key highlight of the second quarter.

                                                  Envision Healthcare (EVHC) Q2 Earnings Beat, Revenues Miss

                                                  by Zacks Equity Research

                                                  Envision Healthcare's (EVHC) second-quarter results were positively impacted by strong Physician Services segment.